Background:
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can cause ICI myocarditis (ICIM), a potentially fatal complication driven by aberrant CD8
+
T-cell responses. Current therapies reduce cardiac inflammation but may compromise anti-tumor immunity. We observed that CXCR3 inhibitio...
Yin Sun, M. R. Vitale, Tanvi Shankar et al.· Circulation· 0 citations
Hypertrophic cardiomyopathy is a leading cause of sudden cardiac death, often driven by pathogenic variants in sarcomeric genes such as MYBPC3. The precise electrophysiological mechanisms underlying arrhythmogenesis in HCM, particularly in the context of MYBPC3 truncating mutations, remain incompletely defined, hinderi...
M. Abdelsayed, E. Gianitsos, Alice Yu et al.· Journal of Molecular and Cel...· 0 citations
The data indicate that pathogenic E-rich domain variants reduce RBM20 protein abundance, but that their mechanism is unlikely to be explained by haploinsufficiency alone.
Bai Fang, Kaiser Chua, Daniel Y. Li et al.· bioRxiv· 0 citations
This work provides a platform for extending genome engineering in induced pluripotent stem cells to multiplexed assays of variant effects across diverse disease-relevant cellular phenotypes, enhancing the understanding of variant pathogenicity and uncovering novel biological mechanisms that could inform therapeutic str...
Yuta Yamamoto, Kaiser Chua, David W. Staudt et al.· Circulation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.